Free Trial

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

$3.97
-0.01 (-0.25%)
(As of 07/12/2024 ET)

Zentalis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$11.33
185.47% Upside
High Forecast$25.00
Average Forecast$11.33
Low Forecast$4.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.33$31.67$38.57$47.10
Forecasted Upside185.47% Upside112.20% Upside137.21% Upside123.19% Upside
Get Zentalis Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

ZNTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZNTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zentalis Pharmaceuticals Stock vs. The Competition

TypeZentalis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.71
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside185.47% Upside994.16% Upside9.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/20/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$28.00 ➝ $5.00+20.77%
6/18/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$42.00 ➝ $6.00+38.25%
6/18/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $8.00+65.97%
6/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $25.00+418.67%
6/18/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$40.00 ➝ $20.00+314.94%
6/18/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$32.00 ➝ $10.00+107.47%
6/18/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Driscoll
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$15.00 ➝ $4.00-33.33%
6/18/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$29.00 ➝ $9.00+40.62%
11/7/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/7/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$15.00+20.19%
11/11/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$55.00 ➝ $28.00+35.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:34 AM ET.

ZNTL Forecast - Frequently Asked Questions

What is Zentalis Pharmaceuticals' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zentalis Pharmaceuticals is $11.33, with a high forecast of $25.00 and a low forecast of $4.00.

Should I buy or sell Zentalis Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZNTL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZNTL, but not buy additional shares or sell existing shares.

Does Zentalis Pharmaceuticals's stock price have much upside?

According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 93.77% based on their 12-month stock forecasts.

Has Zentalis Pharmaceuticals been downgraded by Wall Street analysts recently?

Over the previous 90 days, Zentalis Pharmaceuticals's stock had 3 downgrades by analysts.

What analysts cover Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals has been rated by research analysts at HC Wainwright, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Stifel Nicolaus, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Zentalis Pharmaceuticals more than its competitors?

Analysts like Zentalis Pharmaceuticals less than other "medical" companies. The consensus rating for Zentalis Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZNTL compares to other companies.


This page (NASDAQ:ZNTL) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners